Domestic price of Avatrombopag tablets

Avatrombopag is indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo surgery and for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP; also known as idiopathic thrombocytopenic purpura) who have had an inadequate response to prior treatments (designated as an orphan drug by the FDA for this condition).

Follow recommended dosing guidelines to achieve target platelet count (maintain platelet count ≥50,000/mm3 in patients with immune thrombocytopenia) to minimize bleeding risk; do not use to normalize platelet count. Thrombopoietin receptor agonists (TPO-RAs) are used as second-line therapy for the treatment of chronic immune thrombocytopenia, usually after lack of platelet response to corticosteroids and/or intravenous immunoglobulin (IVIG). Corticosteroids remain the standard initial treatment for patients with newly diagnosed chronic immune thrombocytopenia, but should be used for a limited time due to side effects.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it can only be reimbursed to eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, and the price of 20mg*10 tablets may be more than 5,000 yuan per box. The original drug of avatrombopag marketed overseas is more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).